Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways

Roberto Galuppo, Erin Maynard, Malay Shah, Michael F. Daily, Changguo Chen, Brett T. Spear, Roberto Gedaly

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Background/Aim: The aim of this study is to find synergistic effect using FH535 and sorafenib by targeting the RAS/RAF/MAPK and WNT/β-catenin pathways. Materials and Methods: 3H-Thymidine incorporation assays were performed to address Huh7 and liver cancer stem cell (LCSC) inhibition using FH535 and sorafenib, alone and in combination. Calcusyn analysis was used to calculate the combination index (CI). A western blot assay was performed to check for potential targets. Results: FH535 and sorafenib caused inhibition of Huh7 and LCSC. Combination therapy was significantly better than monotherapy in inhibition of HuH7. Combination with sorafenib and FH535 was found to be synergistic in inhibition of LCSC with a CI of less than 1. The western blot assay demonstrated enhanced cleaved poly (ADP-ribose) polymerase (PARP) and inhibition of cyclin D1, B-cell lymphoma 2 (Bcl2), survivin and cellular myelocytomatosis oncogene (c-MYC). Conclusion: FH535 and sorafenib combination produced synergistic effect on inhibition of HCC and LCSC. Our study demonstrated that FH535 can induce apoptosis in these two different hepatocellular carcinoma (HCC) cell lines.

Original languageEnglish (US)
Pages (from-to)1709-1714
Number of pages6
JournalAnticancer research
Volume34
Issue number4
StatePublished - Apr 1 2014

Keywords

  • Epidermal growth factor
  • Hepatocellular carcinoma
  • Liver cancer stem cells
  • PI-103
  • PKI-587
  • RAS/RAF/MAPK
  • Rapamycin
  • Sorafenib
  • mTOR complex 1
  • mTOR complex 2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways'. Together they form a unique fingerprint.

  • Cite this

    Galuppo, R., Maynard, E., Shah, M., Daily, M. F., Chen, C., Spear, B. T., & Gedaly, R. (2014). Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways. Anticancer research, 34(4), 1709-1714.